CellsBin, a Branford-based biotechnology company pioneering Rare-Cell Biology, closed its Series A financing led by 108 BioCapital to advance its Rare-Cell Intelligence Platform.
The platform integrates advanced microfluidics, patented multimodal imaging, single-cell analysis, and artificial intelligence to make rare cells visible, measurable, and actionable, combining ultrasensitive rare-cell detection, high-dimensional cellular profiling, and AI-driven analysis to help researchers and clinicians understand how therapeutic cells behave and why patients respond differently to cell therapy. CellsBin's initial applications focus on cell and gene therapy monitoring and hematologic cancers.
Sasha Bakhru, Managing Partner of 108 BioCapital, said, "CellsBin is building a differentiated platform at the intersection of single-cell biology, artificial intelligence and translational medicine. Its ability to detect and characterize extremely rare cells could unlock important insights into therapeutic response, disease progression and patient outcomes. We have been impressed by Ali and the CellsBin team's scientific rigor, platform vision and commitment to translating complex biology into actionable intelligence."
CellsBin will use the proceeds to accelerate commercial adoption, expand strategic and channel partnerships, advance its research and product-development roadmap, and grow its commercial, scientific, and technical teams, working to enable smarter decisions and earlier care through applications in precision diagnostics and translational research.
"We are excited to partner with CellsBin and support the company as it expands its network of strategic, clinical and commercial relationships," said Shahryar Oveissi, General Partner of 108 BioCapital. "We are already seeing strong interest from leading healthcare institutions in CellsBin's technology and its potential to create meaningful clinical impact."
Ali Kabiri, PhD, Co-founder and Chief Executive Officer of CellsBin, said, "This financing represents an important milestone in our mission to make rare cells visible, measurable and clinically actionable. 108 BioCapital shares our conviction that rare cells contain critical biological information that can enable earlier, more precise and more confident decisions."
